C2B2 has been awarded a contract to serve as the Data Analysis and Coordination Center for the International Serious Adverse Event Consortium (iSAEC). iSAEC is a nonprofit organization comprising leading pharmaceutical companies and academic institutions with scientific and strategic input from the U.S. Food and Drug Administration (FDA). Using the power of whole genome association (WGA) studies, iSAEC aims to (i) identify and validate DNA-variants useful in predicting the risk of drug-related serious adverse events, and (ii) make such discoveries freely available to the research community for further investigations. C2B2 will provide  computational infrastructure for the storage and analysis of the WGA data as well as information systems for the dissemination of the analysis results to the public.